A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.

The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).

The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).

A simple, natural method of preserving organisms includes sealing biological blood or organisms in a shell filled with resin, curing the resin, and solidifying the shell for a long time to form amber. The biological blood or organisms can be preserved for a long time. Scholars of later generations may research the integrity of the biological blood or organisms of the present days. Otherwise, the biological blood or organisms may be of no researching meaning and purposes due to pollution or oxidation and dehydration. The organisms of the present days may be reconstructed after 100 years by using technologies of that time. Thus, the organisms being extinct due to pollution can be reconstructed. Diversities of organisms on the earth can be maintained. Precious genes of the organisms of the present days can be preserved for thousands years. It contributes greatly to the study of evolution of organisms.

Disclosed are devices and methods for non-cryogenic vitrification of biological materials that include the steps of providing one or more capillary channels of which a first opening is operably in contact with a moisture containing vitrification mixture made of a biological material and a vitrification agent.

Methods for stabilizing blood samples, e.g., clinical blood samples, for storage or transportation before use. Exemplary applications include but are not limited to enrichment of leukocyte subtypes such as T-cells or neutrophils for cytokine and immuno-assays; isolation of progenitor cells from cord blood or peripheral blood for transplantation; isolation of fetal cells from the maternal blood for diagnosis; and sorting of circulating tumor cells for cancer detection and therapy.

A method of preparing isolated body tissue (10) for cryogenic storage, the method comprising a step of actively infusing the body tissue (10) with a cryoprotectant (20). Additionally, a kit for preparing umbilical cord tissue (10) for cryogenic storage, comprising a cryoprotectant (20) and infusion means (22) for actively infusing the umbilical cord tissue (10) with the cryoprotectant (20).

This disclosure relates to scale-down systems for freezing and thawing aqueous liquid mixtures of thermo sensitive substances. In at least one aspect, the system can comprise a first container that has a head-space and a liquid-space, with a substantially constant average transversal cross-section area in the liquid-space that does not change substantially with height. The first container holds a volume of liquid for a height of liquid, has a lateral active heat transfer area having an insulated lateral area ALIM, and has an equivalent radius sized to reproduce the equivalent radius of a second container. The first container further has a lateral heat transfer area in contact with the liquid-space. The first container is smaller than the second container, and the insulated lateral area is equal to or greater than the lateral active heat transfer area.

This disclosure is in the field of cancer immunotherapy and relates to all cancer types, including but not limited to cancers of the breast, lung, prostate, pancreas, colon, bladder, brain, head-neck, kidney, esophagus, skin, and blood cells. The embodiments provide methods for selecting and amplifying specific targeting molecules to use in therapy and diagnostic testing. Targets include but are not necessarily limited to architecturally preserved, usually heterogeneous specific surface structures present on individual cancer cells and cancer stem cells but not on non-malignant cells. The embodiments are novel in that they provide these binding molecules for one individual's cancer regardless of the rarity of an individual cancer cell or stem cell and promptly enough to initiate treatment without requiring lengthy immunization or hybridoma production that are current art.

A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.